1. HBW Insight

OTC Sildenafil Not Coming To Australia Any Time Soon

 
• By Tom Gallen

Australian government finds an insufficient body of new evidence to support Rx-to-OTC switch of erectile dysfunction drug sildenafil since it was last considered in 2020.

Australia Dollars Currency Map
• Source: Alamy

Australia has rejected for the fourth time the Rx-to-OTC switch of erectile dysfunction treatment sildenafil.

A delegate of Australia’s department of Health and Aged Care who made the decision cited an “insufficient body of new evidence” to support

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

More from Ingredients & Safety

German Industry Urges ECHA To Reconsider ‘De Facto’ EU Ethanol Ban

 
• By David Ridley

Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.

AESGP: ‘No Evidence’ Of Antimicrobial Resistance With OTC Antifungals Or Antivirals

 
• By David Ridley

Two AESGP papers reviewing the evidence for AMR risk associated with a range of OTC antifungals and antivirals conclude there is litte to no risk associated with the responsible self-care use of such medicines.

AESGP Slams ‘Deeply Concerning And Discriminatory’ EU Wastewater Directive

 
• By David Ridley

“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.